Literature DB >> 17723085

Interference of maltose, icodextrin, galactose, or xylose with some blood glucose monitoring systems.

Thomas G Schleis1.   

Abstract

Maltose, a disaccharide composed of two glucose molecules, is used in a number of biological preparations as a stabilizing agent or osmolality regulator. Icodextrin, which is converted to maltose, is present in a peritoneal dialysis solution. Galactose and xylose are found in some foods, herbs, and dietary supplements; they are also used in diagnostic tests. When some blood glucose monitoring systems are used--specifically, those that use test strips containing the enzymes glucose dehydrogenase-pyrroloquinolinequinone or glucose dye oxidoreductase--in patients receiving maltose, icodextrin, galactose, or xylose, interference of blood glucose levels can occur. Maltose, icodextrin, galactose, and xylose are misinterpreted as glucose, which can result in erroneously elevated serum glucose levels. This interference can result in the administration of insulin, which may lead to hypoglycemia. In severe cases of hypoglycemia, deaths have occurred. If patients are receiving maltose, icodextrin, galactose, or xylose, clinicians must review the package inserts of all test strips to determine the type of glucose monitoring system being used and to use only those systems whose tests strips contain glucose oxidase, glucose dehydrogenase-nicotinamide adenine dinucleotide, or glucose dehydrogenase-flavin adenine dinucleotide.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723085     DOI: 10.1592/phco.27.9.1313

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  20 in total

1.  System accuracy evaluation for blood glucose measurements should be performed in accordance with ISO 15197:2003 and CLSI-approved guideline EP7-A2.

Authors:  Rolf Hinzmann; Cam-Tuan Tran
Journal:  Diabetes Technol Ther       Date:  2012-02-15       Impact factor: 6.118

2.  Regulatory controversies surround blood glucose monitoring devices.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2010-03-01

Review 3.  Factors affecting blood glucose monitoring: sources of errors in measurement.

Authors:  Barry H Ginsberg
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

4.  Hematocrit interference of blood glucose meters for patient self-measurement.

Authors:  Sanja Ramljak; John Paul Lock; Christina Schipper; Petra B Musholt; Thomas Forst; Martha Lyon; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

5.  Assessment of the effects of repeated freeze thawing and extended bench top processing of plasma samples using untargeted metabolomics.

Authors:  Kelli Goodman; Matthew Mitchell; Anne M Evans; Luke A D Miller; Lisa Ford; Bryan Wittmann; Adam D Kennedy; Douglas Toal
Journal:  Metabolomics       Date:  2021-03-11       Impact factor: 4.290

6.  White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism.

Authors:  Michael S Hofman; Rodney J Hicks
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

7.  A Simulation Study to Assess the Effect of Analytic Error on Neonatal Glucose Measurements Using the Canadian Pediatric Society Position Statement Action Thresholds.

Authors:  Mark Inman; Kayla Parker; Lannae Strueby; Andrew W Lyon; Martha E Lyon
Journal:  J Diabetes Sci Technol       Date:  2019-11-06

8.  In Vitro Sugar Interference Testing With Amperometric Glucose Oxidase Sensors.

Authors:  Ryan Boehm; John Donovan; Disha Sheth; Andrew Durfor; Jason Roberts; Irada Isayeva
Journal:  J Diabetes Sci Technol       Date:  2018-08-03

9.  Finger-stick glucose monitoring: issues of accuracy and specificity.

Authors:  Leann Olansky; Laurence Kennedy
Journal:  Diabetes Care       Date:  2010-04       Impact factor: 19.112

Review 10.  Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG.

Authors:  Eva Morava
Journal:  Mol Genet Metab       Date:  2014-06-21       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.